Post-Graduate Medical Institute, Lahore Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT04665284
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Lahore General Hospital | PGMI, Lahore | Post Graduate Medical Institute | Post-Graduate Medical Institute, Lahore General Hospital, Lahore Pakistan

Active Ingredients

Drugs in Phase 4 Trials (1)

empagliflozin (jardiance) (1 trial)

Drugs in Phase 3 Trials (1)

honey (1 trial)

Drugs in Phase 1 Trials (3)

COVID-19 convalescent plasma (1 trial)

remdesivir (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Other Trials (1)

methylprednisolone (medrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 1)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Severe Acute Respiratory Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6